Phase II trial with Flavone Acetic Acid (NSC.347512, LM975) in patients with non-small cell lung cancer.
Siegenthaler
P
P
Oncology Unit, Hôpital des Cadolles, Neuchâtel, Switzerland.
Kaye
S B
SB
Monfardini
S
S
Renard
J
J
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D005419:Flavonoids; C049328:flavone acetic acid